Dietary supplement sector inspires confidence
When multiple multinational companies start investing their acquisition monies into one particular category, it’s a good bet that category is poised for some pretty significant growth.
(For the full category review, including sales data, click here.)
Right now, that category is dietary supplements. “Over the past 10 years, the industry has gone from $20 billion to $32.5 billion,” Council for Responsible Nutrition president and CEO Steve Mister recently told an audience of supplement suppliers. “During that period, the growth of dietary supplements has been the envy of other sectors of the economy.”
According to CRN consumer surveys, 85% of Americans — including those who don’t take supplements on a regular basis — are somewhat or very confident in the industry.
And the sales figures back it up. In total U.S. multi-outlets, which doesn’t include such specialty retailers as GNC or health food stores, sales of all vitamins totaled $6.4 billion, up 5.8% for the 52 weeks ended Aug. 11, according to IRI. Almost $350 million more vitamin sales were generated this year versus the year-ago period.
And now — with the likes of Reckitt Benckiser managing a considerable portfolio featuring both Schiff and Airborne; with Church and Dwight getting excited over the opportunities within adult gummy vitamins; and with Procter and Gamble’s acquisition of a full line of supplements that it has yet to introduce into mass — that $350 million in annual growth dollars may represent just the beginning of a prolonged winning streak for health-and-wellness purveyors.
Beyond the aging of the baby boomer, an escalating emphasis on consumer-driven healthcare ought to serve as growth catalysts. Three hot trends include the gummy format for adults, probiotics and an immune boosting adjacency to cough-cold.
Topical BioMedics gains national distribution for Topricin Foot Therapy Cream
RHINEBECK, N.Y. — Topical BioMedics recently announced distribution through CVS/pharmacy for its Topricin Foot Therapy Cream, a homeopathic topical treatment for pain associated with fibromyalgia and neuropathy that is safe for diabetics.
“We are delighted that Topricin Foot Therapy Cream has been chosen by CVS for inclusion in its foot care section,” stated Lou Paradise, Topical BioMedics’ president and chief of research. “It is estimated that more than 20 million Americans suffer from neuropathy, and 60% of all diabetic patients experience neuropathy in their feet, which can be painfully debilitating and greatly impacts their quality of life. Because our formula is patented for the treatment of pain associated with neuropathy, it offers a safe, effective option for people suffering from both diabetic and chemo-induced neuropathy."
Topricin Foot Therapy Cream has been specially formulated to address pains associated with foot and ankle pain and injuries, including gout, heel spurs, bunions and such sports injuries as Plantar fasciitis, Achilles tendonitis and shin splints, as well as neuropathic pain, the company reported.
Fuse Science launches ad campaign supporting Powered By Fuse energy products
MIAMI LAKES, Fla. — Fuse Science on Monday announced that as of late last month it has officially launched its ad campaign behind Powered By Fuse energy products.
"We are now firmly in the roll-out of our commercial advertising and encouraged by initial responses to the Powered By Fuse message," stated Brian Tuffin, CEO Fuse Science. "In addition, we are currently shipping new display units to participating Duane Reade locations which is part of our continued expansion of our distribution footprint and supported by a series of new commercial and print ads that are designed to drive product trial and repeat purchase while leveraging our world-class athletes."
Celebrity endorsers include pro golfing legend Tiger Woods, Boston Red Sox hitter David Ortiz and one of the judges on "Shark Tank," Daymond John.